An Aggressive Form of Langerhan Cell Histiocytosis in an Adult: Therapeutic Challenges
Langerhans cell histiocytosis (LCH) is rare in adults. Regular follow-up is mandatory due to reoccurrence. A 35-year-old male with an incidental left iliac bone lesion was diagnosed with LCH. He later became symptomatic with hip pain and spread of the disease. Despite excision of the symptomatic ili...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2017/9064326 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548955484848128 |
|---|---|
| author | Karan Seegobin Satish Maharaj Cherisse Baldeo Amal Shukri Fauzia N. Rana |
| author_facet | Karan Seegobin Satish Maharaj Cherisse Baldeo Amal Shukri Fauzia N. Rana |
| author_sort | Karan Seegobin |
| collection | DOAJ |
| description | Langerhans cell histiocytosis (LCH) is rare in adults. Regular follow-up is mandatory due to reoccurrence. A 35-year-old male with an incidental left iliac bone lesion was diagnosed with LCH. He later became symptomatic with hip pain and spread of the disease. Despite excision of the symptomatic iliac lesion, he had progression while on cytarabine and nivolumab, evidenced by increased bone pain and involvement of other bones on imaging. He underwent excision of the jaw lesion followed by vinblastine; he was pain free and had stable disease on PET imaging after 3 months. LCH is an uncommon neoplasia. Treatment is reserved for symptomatic patients while asymptomatic patients are observed. Follow-up is imperative due to the risk of reoccurrence. Despite surgical treatment together with one of the front-line agents for refractory disease, in this case cytarabine, he still had progression of the disease. Furthermore, the trial of nivolumab was of no benefit. This case highlights good response to vinblastine which is previously reported to have good success. No trials are published, and the optimal strategy has yet to be defined. LCH with multiple bony involvement can be aggressive and therapeutically challenging. |
| format | Article |
| id | doaj-art-739e1e4690e047229b4d042e500996ec |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-739e1e4690e047229b4d042e500996ec2025-02-03T06:12:37ZengWileyCase Reports in Oncological Medicine2090-67062090-67142017-01-01201710.1155/2017/90643269064326An Aggressive Form of Langerhan Cell Histiocytosis in an Adult: Therapeutic ChallengesKaran Seegobin0Satish Maharaj1Cherisse Baldeo2Amal Shukri3Fauzia N. Rana4Department of Internal Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USADepartment of Internal Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USADepartment of Internal Medicine, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USADepartment of Pathology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USADepartment of Haematology and Oncology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USALangerhans cell histiocytosis (LCH) is rare in adults. Regular follow-up is mandatory due to reoccurrence. A 35-year-old male with an incidental left iliac bone lesion was diagnosed with LCH. He later became symptomatic with hip pain and spread of the disease. Despite excision of the symptomatic iliac lesion, he had progression while on cytarabine and nivolumab, evidenced by increased bone pain and involvement of other bones on imaging. He underwent excision of the jaw lesion followed by vinblastine; he was pain free and had stable disease on PET imaging after 3 months. LCH is an uncommon neoplasia. Treatment is reserved for symptomatic patients while asymptomatic patients are observed. Follow-up is imperative due to the risk of reoccurrence. Despite surgical treatment together with one of the front-line agents for refractory disease, in this case cytarabine, he still had progression of the disease. Furthermore, the trial of nivolumab was of no benefit. This case highlights good response to vinblastine which is previously reported to have good success. No trials are published, and the optimal strategy has yet to be defined. LCH with multiple bony involvement can be aggressive and therapeutically challenging.http://dx.doi.org/10.1155/2017/9064326 |
| spellingShingle | Karan Seegobin Satish Maharaj Cherisse Baldeo Amal Shukri Fauzia N. Rana An Aggressive Form of Langerhan Cell Histiocytosis in an Adult: Therapeutic Challenges Case Reports in Oncological Medicine |
| title | An Aggressive Form of Langerhan Cell Histiocytosis in an Adult: Therapeutic Challenges |
| title_full | An Aggressive Form of Langerhan Cell Histiocytosis in an Adult: Therapeutic Challenges |
| title_fullStr | An Aggressive Form of Langerhan Cell Histiocytosis in an Adult: Therapeutic Challenges |
| title_full_unstemmed | An Aggressive Form of Langerhan Cell Histiocytosis in an Adult: Therapeutic Challenges |
| title_short | An Aggressive Form of Langerhan Cell Histiocytosis in an Adult: Therapeutic Challenges |
| title_sort | aggressive form of langerhan cell histiocytosis in an adult therapeutic challenges |
| url | http://dx.doi.org/10.1155/2017/9064326 |
| work_keys_str_mv | AT karanseegobin anaggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges AT satishmaharaj anaggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges AT cherissebaldeo anaggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges AT amalshukri anaggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges AT fauzianrana anaggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges AT karanseegobin aggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges AT satishmaharaj aggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges AT cherissebaldeo aggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges AT amalshukri aggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges AT fauzianrana aggressiveformoflangerhancellhistiocytosisinanadulttherapeuticchallenges |